Prothena reported $2.42M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
Acadia Pharmaceuticals USD 8.06M 277K Mar/2026
Agios Pharmaceuticals USD 10.8M 1.62M Mar/2026
ALKERMES USD 8.54M 3.59M Mar/2026
Alnylam Pharmaceuticals USD 26.6M 32K Mar/2026
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Exelixis USD 16.13M 1.3M Mar/2026
Immunic USD -0.24 0.03 Sep/2024
Incyte USD 38.12M 4.43M Jun/2026
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
MacroGenics USD 1.55M 26K Mar/2026
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Prothena USD 2.42M 935K Mar/2026
Regeneron Pharmaceuticals USD 183.3M 200K Jun/2026
Ultragenyx Pharmaceutical USD 6M 512K Mar/2026
Vertex Pharmaceuticals USD 114.8M 7.1M Mar/2026